• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Finch Therapeutics’ C. Difficile drug gets breakthrough status pharmaceutical-technology
    February 13, 2019
    Microbial therapies developer Finch Therapeutics has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its investigational CP101 drug to treat recurrent Clostridium difficile (C. difficile) infection.....
  • Finch Therapeutics Group Raises $36 Million in Series B Financing firstwordpharma
    March 02, 2018
    Finch Therapeutics Group, Inc. (Finch) announced today the successful close of an oversubscribed $36 million Series B financing, bringing the total capital raised since the Company's launch to $77 million.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service